Zacks: Brokerages Expect Integra LifeSciences Holdings Co. (NASDAQ:IART) Will Announce Quarterly Sales of $395.52 Million

Analysts expect Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) to report $395.52 million in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Integra LifeSciences’ earnings, with the lowest sales estimate coming in at $393.80 million and the highest estimate coming in at $396.30 million. Integra LifeSciences reported sales of $389.99 million during the same quarter last year, which indicates a positive year over year growth rate of 1.4%. The firm is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Integra LifeSciences will report full-year sales of $1.59 billion for the current fiscal year, with estimates ranging from $1.59 billion to $1.60 billion. For the next financial year, analysts anticipate that the firm will report sales of $1.68 billion, with estimates ranging from $1.67 billion to $1.70 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Integra LifeSciences.

Integra LifeSciences (NASDAQ:IARTGet Rating) last announced its quarterly earnings data on Wednesday, April 27th. The life sciences company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.06. The firm had revenue of $376.60 million during the quarter, compared to analysts’ expectations of $362.19 million. Integra LifeSciences had a net margin of 10.04% and a return on equity of 16.88%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.69 earnings per share.

A number of equities analysts have commented on the stock. Bank of America lifted their price objective on shares of Integra LifeSciences from $55.00 to $65.00 and gave the stock an “underperform” rating in a research note on Tuesday, January 18th. StockNews.com raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, April 30th. Truist Financial lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $72.00 to $71.00 in a report on Wednesday, April 13th. Finally, Piper Sandler decreased their price objective on shares of Integra LifeSciences from $72.00 to $66.00 in a report on Wednesday, February 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $72.80.

IART opened at $59.12 on Monday. The stock has a market capitalization of $4.91 billion, a price-to-earnings ratio of 32.13, a PEG ratio of 1.88 and a beta of 1.10. The company has a fifty day moving average of $63.93 and a 200 day moving average of $65.85. Integra LifeSciences has a fifty-two week low of $58.28 and a fifty-two week high of $76.70. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.34 and a current ratio of 3.38.

In other Integra LifeSciences news, major shareholder Tru St Partnership, L.P. sold 150,000 shares of Integra LifeSciences stock in a transaction that occurred on Wednesday, March 23rd. The shares were sold at an average price of $64.67, for a total transaction of $9,700,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Glenn Coleman sold 6,268 shares of Integra LifeSciences stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $66.04, for a total transaction of $413,938.72. Following the sale, the chief operating officer now owns 41,288 shares of the company’s stock, valued at $2,726,659.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 231,268 shares of company stock worth $15,050,939. 4.20% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Eaton Vance Management lifted its stake in shares of Integra LifeSciences by 2.6% in the 4th quarter. Eaton Vance Management now owns 4,107,343 shares of the life sciences company’s stock valued at $275,029,000 after purchasing an additional 103,505 shares during the period. Alliancebernstein L.P. lifted its stake in shares of Integra LifeSciences by 11.0% in the 4th quarter. Alliancebernstein L.P. now owns 2,329,360 shares of the life sciences company’s stock valued at $156,044,000 after purchasing an additional 231,383 shares during the period. Goldman Sachs Group Inc. raised its position in Integra LifeSciences by 73.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,482,718 shares of the life sciences company’s stock worth $99,327,000 after acquiring an additional 629,202 shares during the period. Dimensional Fund Advisors LP raised its position in Integra LifeSciences by 2.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,356,159 shares of the life sciences company’s stock worth $90,853,000 after acquiring an additional 31,192 shares during the period. Finally, Geode Capital Management LLC raised its position in Integra LifeSciences by 6.0% during the fourth quarter. Geode Capital Management LLC now owns 1,006,447 shares of the life sciences company’s stock worth $67,421,000 after acquiring an additional 57,231 shares during the period. Hedge funds and other institutional investors own 93.32% of the company’s stock.

About Integra LifeSciences (Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Read More

Get a free copy of the Zacks research report on Integra LifeSciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.